Medical Xpress - latest medical and health news stories
Oncotype DX not cost-effective for low-risk breast cancer
Tue, 19 Feb 2019 13:20:02 EST
(HealthDay)—The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk for recurrence, according to research published online Jan. 22 in the Journal of the National Comprehensive Cancer Network.
